BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jones EA, Bergasa NV. The pruritus of cholestasis: from bile acids to opiate agonists. Hepatology. 1990;11:884-887. [PMID: 2161397 DOI: 10.1002/hep.1840110526] [Cited by in Crossref: 141] [Cited by in F6Publishing: 116] [Article Influence: 4.4] [Reference Citation Analysis]
Number Citing Articles
1 Luketic VA, Shiffman ML. BENIGN RECURRENT INTRAHEPATIC CHOLESTASIS. Clinics in Liver Disease 1999;3:509-28. [DOI: 10.1016/s1089-3261(05)70083-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
2 Bergasa NV, Jones EA. THE PRURITUS OF CHOLESTASIS. Clinics in Liver Disease 1998;2:391-405. [DOI: 10.1016/s1089-3261(05)70014-3] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
3 Marchioni Beery RM, Vaziri H, Forouhar F. Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis: a Review Featuring a Women's Health Perspective. J Clin Transl Hepatol 2014;2:266-84. [PMID: 26357630 DOI: 10.14218/JCTH.2014.00024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 9] [Article Influence: 0.1] [Reference Citation Analysis]
4 Ostadhadi S, Foroutan A, Momeny M, Norouzi-javidan A, Azimi E, Kordjazy N, Dehpour AR. Evidence for the involvement of nitric oxide in cholestasis-induced itch associated response in mice. Biomedicine & Pharmacotherapy 2016;84:1367-74. [DOI: 10.1016/j.biopha.2016.10.068] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
5 Mombeini T, Roushanzamir F, Jorjani M, Pourpak Z, Gaskari SA, Mehr SE, Dehpour AR. Alteration in specific opioid-receptor labeling on peripheral blood leukocytes of bile duct-ligated rat. Pathophysiology 2006;13:111-7. [DOI: 10.1016/j.pathophys.2006.02.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
6 Düll MM, Kremer AE. Treatment of Pruritus Secondary to Liver Disease. Curr Gastroenterol Rep 2019;21. [DOI: 10.1007/s11894-019-0713-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 4.3] [Reference Citation Analysis]
7 Bergasa NV. The pruritus of cholestasis: From bile acids to opiate agonists: Relevant after all these years. Medical Hypotheses 2018;110:86-9. [DOI: 10.1016/j.mehy.2017.11.002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
8 Jones EA. Pruritus and fatigue associated with liver disease: is there a role for ondansetron? Expert Opinion on Pharmacotherapy 2008;9:645-51. [DOI: 10.1517/14656566.9.4.645] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
9 Greco PJ, Ende J. Pruritus: A practical approach. J Gen Intern Med 1992;7:340-9. [DOI: 10.1007/bf02598094] [Cited by in Crossref: 6] [Article Influence: 0.2] [Reference Citation Analysis]
10 Mackinnon KL, Zuzel KA, David B. Hepatic inactivation of Leu-enkephalin. Regulatory Peptides 1996;67:85-92. [DOI: 10.1016/s0167-0115(96)00117-6] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
11 Jones EA, Bergasa NV. The pruritus of cholestasis. Hepatology. 1999;29:1003-1006. [PMID: 10094938 DOI: 10.1002/hep.510290450] [Cited by in Crossref: 117] [Cited by in F6Publishing: 91] [Article Influence: 5.1] [Reference Citation Analysis]
12 Bergasa NV, Link MJ, Keogh M, Yaroslavsky G, Rosenthal RN, Mcgee M. Pilot Study of Bright-Light Therapy Reflected Toward the Eyes for the Pruritus of Chronic Liver Disease. American Journal of Gastroenterology 2001;96:1563-70. [DOI: 10.1111/j.1572-0241.2001.03778.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 25] [Article Influence: 1.7] [Reference Citation Analysis]
13 Ghent CN. The pruritus of cholestasis. Hepatology 1999;30:586-7. [DOI: 10.1002/hep.510300228] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
14 Abbas G, Jorgensen RA, Lindor KD. Fatigue in primary biliary cirrhosis. Nat Rev Gastroenterol Hepatol. 2010;7:313-319. [PMID: 20458334 DOI: 10.1038/nrgastro.2010.62] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
15 Neff GW, O'Brien CB, Reddy KR, Bergasa NV, Regev A, Molina E, Amaro R, Rodriguez MJ, Chase V, Jeffers L, Schiff E. Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease. Am J Gastroenterol. 2002;97:2117-2119. [PMID: 12190187 DOI: 10.1111/j.1572-0241.2002.05852.x] [Cited by in Crossref: 88] [Cited by in F6Publishing: 62] [Article Influence: 4.4] [Reference Citation Analysis]
16 Brigman C, Feranchak A. Liver involvement in cystic fibrosis. Curr Treat Options Gastro 2006;9:484-96. [DOI: 10.1007/s11938-006-0005-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
17 Tohda C, Yamaguchi T, Kuraishi Y. Increased expression of mRNA for myocyte-specific enhancer binding factor (MEF) 2C in the cerebral cortex of the itching mouse. Neuroscience Research 1997;29:209-15. [DOI: 10.1016/s0168-0102(97)00090-4] [Cited by in Crossref: 28] [Article Influence: 1.1] [Reference Citation Analysis]
18 Bergasa NV. Lysophosphatidic acid and atotaxin in patients with cholestasis and pruritus: Fine biology, anticipated discernment. Annals of Hepatology 2010;9:475-9. [DOI: 10.1016/s1665-2681(19)31629-1] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
19 Valeria Bergasa N, Alling DW, Vergalla J, Anthony Jones E. Cholestasis in the male rat is associated with naloxone-reversible antinociception. Journal of Hepatology 1994;20:85-90. [DOI: 10.1016/s0168-8278(05)80471-4] [Cited by in Crossref: 82] [Cited by in F6Publishing: 7] [Article Influence: 2.9] [Reference Citation Analysis]
20 Walker KF, Chappell LC, Hague WM, Middleton P, Thornton JG. Pharmacological interventions for treating intrahepatic cholestasis of pregnancy. Cochrane Database Syst Rev 2020;7:CD000493. [PMID: 32716060 DOI: 10.1002/14651858.CD000493.pub3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
21 Parés A, Cisneros L, Salmerón JM, Caballería L, Mas A, Torras A, Rodés J. Extracorporeal albumin dialysis: a procedure for prolonged relief of intractable pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol. 2004;99:1105-1110. [PMID: 15180733 DOI: 10.1111/j.1572-0241.2004.30204.x] [Cited by in Crossref: 77] [Cited by in F6Publishing: 62] [Article Influence: 4.3] [Reference Citation Analysis]
22 Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ; American Association for Study of Liver Diseases. Primary biliary cirrhosis. Hepatology. 2009;50:291-308. [PMID: 19554543 DOI: 10.1002/hep.22906] [Cited by in Crossref: 850] [Cited by in F6Publishing: 705] [Article Influence: 65.4] [Reference Citation Analysis]
23 Cies JJ, Giamalis JN. Treatment of cholestatic pruritus in children. American Journal of Health-System Pharmacy 2007;64:1157-62. [DOI: 10.2146/ajhp060453] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
24 Balistreri WF. Bile acid therapy in pediatric hepatobiliary disease: the role of ursodeoxycholic acid. J Pediatr Gastroenterol Nutr 1997;24:573-89. [PMID: 9161955 DOI: 10.1097/00005176-199705000-00016] [Cited by in Crossref: 61] [Cited by in F6Publishing: 43] [Article Influence: 2.4] [Reference Citation Analysis]
25 Moezi L, Dehpour AR. Cardiovascular abnormalities in obstructive cholestasis: the possible mechanisms. Liver Int 2013;33:7-15. [DOI: 10.1111/j.1478-3231.2012.02803.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
26 Whitington PF. CHRONIC CHOLESTASIS OF INFANCY. Pediatric Clinics of North America 1996;43:1-26. [DOI: 10.1016/s0031-3955(05)70395-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
27 Elias E, Burra P. Primary biliary cirrhosis: symptomatic treatment. J Gastroenterol Hepatol 1991;6:570-3. [PMID: 1782372 DOI: 10.1111/j.1440-1746.1991.tb00912.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
28 Tohda C, Yamaguchi T, Kuraishi Y. Intracisternal Injection of Opioids Induces Itch-Associated Response through μ-Opioid Receptors in Mice. Japanese Journal of Pharmacology 1997;74:77-82. [DOI: 10.1016/s0021-5198(19)31429-5] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
29 Fagan EA. Intrahepatic cholestasis of pregnancy. Clin Liver Dis 1999;3:603-32. [PMID: 11291241 DOI: 10.1016/s1089-3261(05)70087-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
30 Schwörer H, Hartmann H, Ramadori G. Relief of cholestatic pruritus by a novel class of drugs: 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists: effectiveness of ondansetron. Pain 1995;61:33-7. [DOI: 10.1016/0304-3959(94)00145-5] [Cited by in Crossref: 108] [Cited by in F6Publishing: 89] [Article Influence: 4.0] [Reference Citation Analysis]
31 Yerushalmi B, Sokol RJ, Narkewicz MR, Smith D, Karrer FM. Use of rifampin for severe pruritus in children with chronic cholestasis. J Pediatr Gastroenterol Nutr 1999;29:442-7. [PMID: 10512405 DOI: 10.1097/00005176-199910000-00013] [Cited by in Crossref: 73] [Cited by in F6Publishing: 53] [Article Influence: 3.2] [Reference Citation Analysis]
32 Terra SG, Tsunoda SM. Opioid antagonists in the treatment of pruritus from cholestatic liver disease. Ann Pharmacother 1998;32:1228-30. [PMID: 9825091 DOI: 10.1345/aph.18115] [Cited by in Crossref: 30] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
33 Bergasa NV, Talbot TL, Alling DW, Schmitt JM, Walker EC, Baker BL, Korenman JC, Park Y, Hoofnagle JH, Jones EA. A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. Gastroenterology 1992;102:544-9. [PMID: 1732125 DOI: 10.1016/0016-5085(92)90102-5] [Cited by in Crossref: 196] [Cited by in F6Publishing: 167] [Article Influence: 6.5] [Reference Citation Analysis]
34 Kowdley KV, Keeffe EB, Fawaz KA. Prolonged cholestasis due to trimethoprim sulfamethoxazole. Gastroenterology 1992;102:2148-50. [DOI: 10.1016/0016-5085(92)90346-z] [Cited by in Crossref: 44] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
35 Liu XY, Liu ZC, Sun YG, Ross M, Kim S, Tsai FF, Li QF, Jeffry J, Kim JY, Loh HH, Chen ZF. Unidirectional cross-activation of GRPR by MOR1D uncouples itch and analgesia induced by opioids. Cell 2011;147:447-58. [PMID: 22000021 DOI: 10.1016/j.cell.2011.08.043] [Cited by in Crossref: 169] [Cited by in F6Publishing: 159] [Article Influence: 15.4] [Reference Citation Analysis]
36 Pusl T, Beuers U. Extrahepatic manifestations of cholestatic liver diseases: pathogenesis and therapy. Clin Rev Allergy Immunol. 2005;28:147-157. [PMID: 15879620 DOI: 10.1385/criai:28:2:147] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
37 Gurung V, Middleton P, Milan SJ, Hague W, Thornton JG. Interventions for treating cholestasis in pregnancy. Cochrane Database Syst Rev 2013;:CD000493. [PMID: 23794285 DOI: 10.1002/14651858.CD000493.pub2] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
38 Bertolotti M, Ferrari A, Vitale G, Stefani M, Trenti T, Loria P, Carubbi F, Carulli N, Sternieri E. Effect of liver cirrhosis on the systemic availability of naltrexone in humans. J Hepatol 1997;27:505-11. [PMID: 9314128 DOI: 10.1016/s0168-8278(97)80355-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
39 Bergasa NV, Thomas DA, Vergalla J, Turner ML, Jones EA. Plasma from patients with the pruritus of cholestasis induces opioid receptor-mediated scratching in monkeys. Life Sci 1993;53:1253-7. [PMID: 8412484 DOI: 10.1016/0024-3205(93)90569-o] [Cited by in Crossref: 44] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
40 Düll MM, Kremer AE. Newer Approaches to the Management of Pruritus in Cholestatic Liver Disease. Curr Hepatology Rep 2020;19:86-95. [DOI: 10.1007/s11901-020-00517-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
41 Dehpour AR, Sadeghipour HR, Nowroozi A, Akbarloo N. The effect of the serotonergic system on opioid withdrawal-like syndrome in a mouse model of cholestasis. Hum Psychopharmacol 2000;15:423-8. [PMID: 12404304 DOI: 10.1002/1099-1077(200008)15:6<423::AID-HUP214>3.0.CO;2-V] [Cited by in Crossref: 15] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
42 Carbone M, Neuberger J. Liver transplantation in PBC and PSC: Indications and disease recurrence. Clinics and Research in Hepatology and Gastroenterology 2011;35:446-54. [DOI: 10.1016/j.clinre.2011.02.007] [Cited by in Crossref: 48] [Cited by in F6Publishing: 39] [Article Influence: 4.4] [Reference Citation Analysis]
43 Marinangeli F, Guetti C, Angeletti C, Bonetti C, Paladini A, Piroli A, Varrassi G. Intravenous naloxone plus transdermal buprenorphine in cancer pain associated with intractable cholestatic pruritus. J Pain Symptom Manage 2009;38:e5-8. [PMID: 19699606 DOI: 10.1016/j.jpainsymman.2009.05.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
44 Oude Elferink RP, Bolier R, Beuers UH. Lysophosphatidic acid and signaling in sensory neurons. Biochim Biophys Acta 2015;1851:61-5. [PMID: 25218302 DOI: 10.1016/j.bbalip.2014.09.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
45 Franco J. Pruritus. Curr Treat Options Gastro 1999;2:451-6. [DOI: 10.1007/s11938-999-0048-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]
46 Swain MG, Rothman RB, Xu H, Vergalla J, Bergasa NV, Jones E. Endogenous opioids accumulate in plasma in a rat model of acute cholestasis. Gastroenterology 1992;103:630-5. [DOI: 10.1016/0016-5085(92)90857-u] [Cited by in Crossref: 127] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
47 Luketic VA, Shiffman ML. Benign recurrent intrahepatic cholestasis. Clin Liver Dis. 2004;8:133-149, vii. [PMID: 15062197 DOI: 10.1016/s1089-3261(03)00133-8] [Cited by in Crossref: 36] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
48 Bergasa NV. Update on the Treatment of the Pruritus of Cholestasis. Clinics in Liver Disease 2008;12:219-34. [DOI: 10.1016/j.cld.2007.11.009] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
49 Ostadhadi S, Haddadi N, Foroutan A, Azimi E, Elmariah S, Dehpour A. Development of resistance to serotonin-induced itch in bile duct ligated mice. Clin Exp Pharmacol Physiol 2017;44:680-5. [DOI: 10.1111/1440-1681.12752] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
50 Gillespie DA, Vickers CR. Pruritus and cholestasis: Therapeutic options. J Gastroenterol Hepatol 1993;8:168-73. [DOI: 10.1111/j.1440-1746.1993.tb01510.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 0.7] [Reference Citation Analysis]
51 Weisshaar E, Ziethen B, Röhl F, Gollnick H. The antipruritic effect of a 5-HT3 receptor antagonist (tropisetron) is dependent on mast cell depletion - an experimental study. Experimental Dermatology 1999;8:254-60. [DOI: 10.1111/j.1600-0625.1999.tb00379.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
52 Dawson PA, Shneider BL, Hofmann AF. Bile Formation and the Enterohepatic Circulation. Physiology of the Gastrointestinal Tract. Elsevier; 2006. pp. 1437-62. [DOI: 10.1016/b978-012088394-3/50059-3] [Cited by in Crossref: 7] [Article Influence: 0.4] [Reference Citation Analysis]
53 Borgeat A, Wilder-smith OH, Mentha G. Subhypnotic doses of propofol relieve pruritus associated with liver disease. Gastroenterology 1993;104:244-7. [DOI: 10.1016/0016-5085(93)90858-a] [Cited by in Crossref: 46] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
54 Kremer AE, Feramisco J, Reeh PW, Beuers U, Oude Elferink RP. Receptors, cells and circuits involved in pruritus of systemic disorders. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2014;1842:869-92. [DOI: 10.1016/j.bbadis.2014.02.007] [Cited by in Crossref: 58] [Cited by in F6Publishing: 47] [Article Influence: 7.3] [Reference Citation Analysis]
55 Sun Y, Zhang W, Evans JF, Floreani A, Zou Z, Nishio Y, Qi R, Leung PS, Bowlus CL, Gershwin ME. Autotaxin, Pruritus and Primary Biliary Cholangitis (PBC). Autoimmun Rev. 2016;15:795-800. [PMID: 27019050 DOI: 10.1016/j.autrev.2016.03.019] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
56 Reid LD, Hubbell CL. Opioids Modulate Rats’ Propensities to Take Alcoholic Beverages. In: Naranjo CA, Sellers EM, editors. Novel Pharmacological Interventions for Alcoholism. New York: Springer; 1992. pp. 121-34. [DOI: 10.1007/978-1-4612-2878-3_10] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
57 Gingold AR, Bergasa NV. The cannabinoid agonist WIN 55, 212-2 increases nociception threshold in cholestatic rats: implications for the treatment of the pruritus of cholestasis. Life Sciences 2003;73:2741-7. [DOI: 10.1016/s0024-3205(03)00668-4] [Cited by in Crossref: 33] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
58 Dehpour AR, Samini M, Rastegar H, Ardeshiri AJ, Roushanzamir F, Jorjani M, Ahmadiani A. Effect of NMDA receptor antagonist on naloxone-precipitated withdrawal signs in cholestatic mice. Hum Psychopharmacol Clin Exp 2000;15:213-8. [DOI: 10.1002/(sici)1099-1077(200004)15:3<213::aid-hup159>3.0.co;2-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
59 Bergasa NV. Medical palliation of the jaundiced patient with pruritus. Gastroenterol Clin North Am. 2006;35:113-123. [PMID: 16530114 DOI: 10.1016/j.gtc.2005.12.008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
60 Javadi-Paydar M, Ghiassy B, Ebadian S, Rahimi N, Norouzi A, Dehpour AR. Nitric oxide mediates the beneficial effect of chronic naltrexone on cholestasis-induced memory impairment in male rats. Behav Pharmacol 2013;24:195-206. [PMID: 23591123 DOI: 10.1097/FBP.0b013e3283618a8c] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
61 Wahler JB, Swain MG, Carson R, Bergasa NV, Jones EA. Blood-brain barrier permeability is markedly decreased in cholestasis in the rat. Hepatology 1993;17:1103-8. [DOI: 10.1002/hep.1840170625] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 0.5] [Reference Citation Analysis]
62 Reshetnyak VI. Primary biliary cirrhosis: Clinical and laboratory criteria for its diagnosis. World J Gastroenterol 2015; 21(25): 7683-7708 [PMID: 26167070 DOI: 10.3748/wjg.v21.i25.7683] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
63 Bergasa NV. The pruritus of cholestasis: facts. Hepatology 2015;61:2114. [PMID: 25345776 DOI: 10.1002/hep.27582] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
64 Floreani A, Carderi I, Variola A, Rizzotto ER, Nicol J, Bergasa NV. A novel multidrug-resistance protein 2 gene mutation identifies a subgroup of patients with primary biliary cirrhosis and pruritus. Hepatology 2006;43:1152-4. [DOI: 10.1002/hep.21165] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
65 Tominaga M, Takamori K. Recent advances in pathophysiological mechanisms of itch. Expert Review of Dermatology 2014;5:197-212. [DOI: 10.1586/edm.10.7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
66 Bergasa NV. An approach to the management of the pruritus of cholestasis. Clinics in Liver Disease 2004;8:55-66. [DOI: 10.1016/s1089-3261(03)00128-4] [Cited by in Crossref: 9] [Article Influence: 0.5] [Reference Citation Analysis]
67 Pusl T, Beuers U. Extrahepatic manifestations of cholestatic liver diseases: pathogenesis and therapy. Clin Rev Allergy Immunol. 2005;28:147-157. [PMID: 15879620 DOI: 10.1385/criai:] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
68 Matthews SN, Cockerell CJ. Prurigo nodularis in HIV-infected individuals. Int J Dermatol 1998;37:401-9. [PMID: 9646121 DOI: 10.1046/j.1365-4362.1998.00507.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 1.0] [Reference Citation Analysis]
69 Villamil AG, Bandi JC, Galdame OA, Gerona S, Gadano AC. Efficacy of lidocaine in the treatment of pruritus in patients with chronic cholestatic liver diseases. Am J Med. 2005;118:1160-1163. [PMID: 16194649 DOI: 10.1016/j.amjmed.2005.05.031] [Cited by in Crossref: 34] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
70 Szarvas S, Harmon D, Murphy D. Neuraxial opioid-induced pruritus: a review. Journal of Clinical Anesthesia 2003;15:234-9. [DOI: 10.1016/s0952-8180(02)00501-9] [Cited by in Crossref: 122] [Cited by in F6Publishing: 33] [Article Influence: 6.4] [Reference Citation Analysis]
71 Dehpour AR, Meysami F, Ebrahimi-daryani N, Akbarloo N. Inhibition by lithium of opioid withdrawal-like syndrome and physical dependency in a model of acute cholestasis in mice. Hum Psychopharmacol Clin Exp 1998;13:407-12. [DOI: 10.1002/(sici)1099-1077(199808)13:6<407::aid-hup11>3.0.co;2-c] [Cited by in Crossref: 11] [Article Influence: 0.5] [Reference Citation Analysis]
72 Aldersley MA, O'Grady JG. Hepatic disorders. Features and appropriate management. Drugs 1995;49:83-102. [PMID: 7705218 DOI: 10.2165/00003495-199549010-00007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
73 Bergasa NV, Mehlman JK, Jones EA. Pruritus and fatigue in primary biliary cirrhosis. Baillieres Best Pract Res Clin Gastroenterol. 2000;14:643-655. [PMID: 10976020 DOI: 10.1053/bega.2000.0109] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 2.0] [Reference Citation Analysis]
74 Kumada H, Miyakawa H, Muramatsu T, Ando N, Oh T, Takamori K, Nakamoto H. Efficacy of nalfurafine hydrochloride in patients with chronic liver disease with refractory pruritus: A randomized, double-blind trial. Hepatol Res. 2017;47:972-982. [PMID: 27753159 DOI: 10.1111/hepr.12830] [Cited by in Crossref: 49] [Cited by in F6Publishing: 38] [Article Influence: 8.2] [Reference Citation Analysis]
75 Fisher DA, Wright TL. Pruritus as a symptom of hepatitis C. J Am Acad Dermatol. 1994;30:629-632. [PMID: 7710472 DOI: 10.1016/s0190-9622(94)70072-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
76 Kamimura K, Yokoo T, Kamimura H, Sakamaki A, Abe S, Tsuchiya A, Takamura M, Kawai H, Yamagiwa S, Terai S. Long-term efficacy and safety of nalfurafine hydrochloride on pruritus in chronic liver disease patients: Patient-reported outcome based analyses. PLoS One. 2017;12:e0178991. [PMID: 28604788 DOI: 10.1371/journal.pone.0178991] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 5.4] [Reference Citation Analysis]
77 Babatin MA, Sanai FM, Swain MG. Methotrexate therapy for the symptomatic treatment of primary biliary cirrhosis patients, who are biochemical incomplete responders to ursodeoxycholic acid therapy. Aliment Pharmacol Ther 2006;24:813-20. [PMID: 16918885 DOI: 10.1111/j.1365-2036.2006.03048.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
78 Trivedi M, V. Bergasa N. Serum concentrations of substance P in cholestasis. Annals of Hepatology 2010;9:177-80. [DOI: 10.1016/s1665-2681(19)31658-8] [Cited by in Crossref: 31] [Article Influence: 2.6] [Reference Citation Analysis]
79 Bosonnet L. Pruritus: scratching the surface. Eur J Cancer Care (Engl). 2003;12:162-165. [PMID: 12787014 DOI: 10.1046/j.1365-2354.2003.00395.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
80 Bergasa NV. Pruritus in primary biliary cirrhosis: pathogenesis and therapy. Clin Liver Dis. 2008;12:385-406; x. [PMID: 18456187 DOI: 10.1016/j.cld.2008.02.013] [Cited by in Crossref: 40] [Cited by in F6Publishing: 30] [Article Influence: 2.9] [Reference Citation Analysis]
81 Bergasa NV. The pruritus of cholestasis. Semin Dermatol 1995;14:302-12. [PMID: 8679436 DOI: 10.1016/s1085-5629(05)80052-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
82 Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology. 2019;69:394-419. [PMID: 30070375 DOI: 10.1002/hep.30145] [Cited by in Crossref: 86] [Cited by in F6Publishing: 92] [Article Influence: 21.5] [Reference Citation Analysis]
83 Carey EJ, Ali AH, Lindor KD. Primary biliary cirrhosis. Lancet. 2015;386:1565-1575. [PMID: 26364546 DOI: 10.1016/s0140-6736(15)00154-3] [Cited by in Crossref: 277] [Cited by in F6Publishing: 121] [Article Influence: 39.6] [Reference Citation Analysis]
84 Binder A, Koroschetz J, Baron R. Disease mechanisms in neuropathic itch. Nat Rev Neurol 2008;4:329-37. [DOI: 10.1038/ncpneuro0806] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 3.2] [Reference Citation Analysis]
85 Neuberger J, Lombard M, Galbraith R. Primary biliary cirrhosis. Gut 1991;Suppl:S73-8. [PMID: 1916473 DOI: 10.1136/gut.32.suppl.s73] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
86 Ghafourifar P, Dehpour AR, Akbarloo N. Inhibition by L-NA, a nitric oxide synthase inhibitor, of naloxone-precpitated withdrawal signs in a mouse model of cholestasis. Life Sciences 1997;60:PL265-70. [DOI: 10.1016/s0024-3205(97)00115-x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 1] [Article Influence: 1.1] [Reference Citation Analysis]
87 Eisendle K, Müller H, Ortner E, Talasz H, Graziadei I, Vogel W, Höpfl R. Pruritus of unknown origin and elevated total serum bile acid levels in patients without clinically apparent liver disease. J Gastroenterol Hepatol. 2011;26:716-721. [PMID: 21155876 DOI: 10.1111/j.1440-1746.2010.06522.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
88 Gaskari SA, Mani AR, Ejtemaei-Mehr S, Namiranian K, Homayoun H, Ahmadi H, Dehpour AR. Do endogenous opioids contribute to the bradycardia of rats with obstructive cholestasis? Fundam Clin Pharmacol 2002;16:273-9. [PMID: 12570015 DOI: 10.1046/j.1472-8206.2002.00089.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 1.5] [Reference Citation Analysis]
89 Bergasa NV, Rothman RB, Vergalla J, Xu H, Swain MG, Jones E. Central mu-opioid receptors are down-regulated in a rat model of cholestasis. Journal of Hepatology 1992;15:220-4. [DOI: 10.1016/0168-8278(92)90040-v] [Cited by in Crossref: 91] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
90 Malik A, Kardashian AA, Zakharia K, Bowlus CL, Tabibian JH. Preventative care in cholestatic liver disease: Pearls for the specialist and subspecialist. Liver Res 2019;3:118-27. [PMID: 32042471 DOI: 10.1016/j.livres.2019.04.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
91 Kronsten V, Fitzpatrick E, Baker A. Management of cholestatic pruritus in paediatric patients with alagille syndrome: the King's College Hospital experience. J Pediatr Gastroenterol Nutr 2013;57:149-54. [PMID: 23619030 DOI: 10.1097/MPG.0b013e318297e384] [Cited by in Crossref: 39] [Cited by in F6Publishing: 7] [Article Influence: 4.9] [Reference Citation Analysis]
92 Imam MH, Gossard AA, Sinakos E, Lindor KD. Pathogenesis and management of pruritus in cholestatic liver disease. J Gastroenterol Hepatol. 2012;27:1150-1158. [PMID: 22413872 DOI: 10.1111/j.1440-1746.2012.07109.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
93 Kremer AE, Oude Elferink RP, Beuers U. Pathophysiology and current management of pruritus in liver disease. Clin Res Hepatol Gastroenterol. 2011;35:89-97. [PMID: 21809485 DOI: 10.1016/j.clinre.2010.10.007] [Cited by in Crossref: 66] [Cited by in F6Publishing: 57] [Article Influence: 6.0] [Reference Citation Analysis]
94 Krishnan A, Koo J. Psyche, opioids, and itch: therapeutic consequences: Psyche, opioids, and itch. Dermatologic Therapy 2005;18:314-22. [DOI: 10.1111/j.1529-8019.2005.00038.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
95 Siddique A, Kowdley KV. Approach to a patient with elevated serum alkaline phosphatase. Clin Liver Dis. 2012;16:199-229. [PMID: 22541695 DOI: 10.1016/j.cld.2012.03.012] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
96 Kuraishi Y, Yamaguchi T, Miyamoto T. Itch-scratch responses induced by opioids through central Mu opioid receptors in mice. J Biomed Sci 2000;7:248-52. [DOI: 10.1007/bf02255473] [Cited by in Crossref: 46] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
97 Terg R, Coronel E, Sordá J, Muñoz AE, Findor J. Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. J Hepatol 2002;37:717-22. [PMID: 12445410 DOI: 10.1016/s0168-8278(02)00318-5] [Cited by in Crossref: 113] [Cited by in F6Publishing: 22] [Article Influence: 5.9] [Reference Citation Analysis]
98 Bergasa NV. Studying pruritus in the 21st century. Clinical Gastroenterology and Hepatology 2003;1:249-51. [DOI: 10.1016/s1542-3565(03)00140-x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
99 Tomer G, Shneider BL. Disorders of bile formation and biliary transport. Gastroenterology Clinics of North America 2003;32:839-55. [DOI: 10.1016/s0889-8553(03)00044-x] [Cited by in Crossref: 14] [Article Influence: 0.7] [Reference Citation Analysis]
100 Bergasa NV. The pruritus of cholestasis. J Hepatol. 2005;43:1078-1088. [PMID: 16253381 DOI: 10.1016/j.jhep.2005.09.004] [Cited by in Crossref: 82] [Cited by in F6Publishing: 58] [Article Influence: 4.8] [Reference Citation Analysis]
101 Reyes H. THE SPECTRUM OF LIVER AND GASTROINTESTINAL DISEASE SEEN IN CHOLESTASIS OF PREGNANCY. Gastroenterology Clinics of North America 1992;21:905-21. [DOI: 10.1016/s0889-8553(21)00609-9] [Cited by in Crossref: 39] [Article Influence: 1.3] [Reference Citation Analysis]
102 Mansour-Ghanaei F, Taheri A, Froutan H, Ghofrani H, Nasiri-Toosi M, Bagherzadeh AH, Farahvash MJ, Mirmomen S, Ebrahimi-Dariani N, Farhangi E, Pourrasouli Z. Effect of oral naltrexone on pruritus in cholestatic patients. World J Gastroenterol 2006; 12(7): 1125-1128 [PMID: 16534857 DOI: 10.3748/wjg.v12.i7.1125] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 37] [Article Influence: 3.1] [Reference Citation Analysis]
103 Bergasa NV, Mohajer B, Maisonneuve IM, Ho A, Maidment NT, Olive F, Gunduz M, Kreek MJ. Basal total opioid peptide release in the striatum of rats with cholestasis from bile duct resection: a study by the use of in vivo microdialysis. Life Sci 1997;61:1169-75. [PMID: 9315507 DOI: 10.1016/s0024-3205(97)00658-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
104 Bhandari BM, Bayat H, Rothstein KD. Primary biliary cirrhosis. Gastroenterol Clin North Am. 2011;40:373-386, viii. [PMID: 21601785 DOI: 10.1016/j.gtc.2011.03.008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
105 Saab S, Han S, Martin P. LIVER TRANSPLANTATION. Clinics in Liver Disease 2000;4:513-32. [DOI: 10.1016/s1089-3261(05)70124-0] [Cited by in Crossref: 8] [Article Influence: 0.4] [Reference Citation Analysis]
106 Hasanein P, Parviz M, Keshavarz M, Javanmardi K, Allahtavakoli M, Ghaseminejad M. Modulation of cholestasis-induced antinociception in rats by two NMDA receptor antagonists: MK-801 and magnesium sulfate. Eur J Pharmacol 2007;554:123-7. [PMID: 17107671 DOI: 10.1016/j.ejphar.2006.10.026] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
107 Tian B, Wang XL, Huang Y, Chen LH, Cheng RX, Zhou FM, Guo R, Li JC, Liu T. Peripheral and spinal 5-HT receptors participate in cholestatic itch and antinociception induced by bile duct ligation in rats. Sci Rep 2016;6:36286. [PMID: 27824106 DOI: 10.1038/srep36286] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
108 Bunchorntavakul C, Reddy KR. Pruritus in chronic cholestatic liver disease. Clin Liver Dis 2012;16:331-46. [PMID: 22541702 DOI: 10.1016/j.cld.2012.03.010] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 3.5] [Reference Citation Analysis]
109 Kremer AE, Beuers U, Oude-Elferink RP, Pusl T. Pathogenesis and treatment of pruritus in cholestasis. Drugs. 2008;68:2163-2182. [PMID: 18840005 DOI: 10.2165/00003495-200868150-00006] [Cited by in Crossref: 77] [Cited by in F6Publishing: 58] [Article Influence: 5.9] [Reference Citation Analysis]
110 Khandelwal M, Malet PF. Pruritus associated with cholestasis. A review of pathogenesis and management. Dig Dis Sci 1994;39:1-8. [PMID: 8281842 DOI: 10.1007/BF02090052] [Cited by in Crossref: 36] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
111 Aftergut K, Cockerell CJ. UPDATE ON THE CUTANEOUS MANIFESTATIONS OF HIV INFECTION. Dermatologic Clinics 1999;17:445-71. [DOI: 10.1016/s0733-8635(05)70101-7] [Cited by in Crossref: 31] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
112 Feuer G, Di Fonzo CJ. Intrahepatic cholestasis: a review of biochemical-pathological mechanisms. Drug Metabol Drug Interact. 1992;10:1-161. [PMID: 1511611 DOI: 10.1515/dmdi.1992.10.1-2.1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
113 Bergasa NV. Pruritus and fatigue in primary biliary cirrhosis. Clin Liver Dis. 2003;7:879-900. [PMID: 14594135 DOI: 10.1016/s1089-3261(03)00105-3] [Cited by in Crossref: 33] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
114 Janas RM, Socha J, Warnawin K, Rujner J. Further studies on aminopeptidase-M in blood in children with cholestatic liver diseases and viral hepatitis. Dig Dis Sci 1999;44:170-6. [PMID: 9952239 DOI: 10.1023/a:1026626822298] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
115 Bergasa NV. Treatment of the pruritus of cholestasis. Curr Treat Options Gastro 2004;7:501-8. [DOI: 10.1007/s11938-004-0009-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
116 Squires RH. End-stage liver disease in children. Curr Treat Options Gastro 2001;4:409-21. [DOI: 10.1007/s11938-001-0006-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
117 Crosignani A, Battezzati PM, Invernizzi P, Selmi C, Prina E, Podda M. Clinical features and management of primary biliary cirrhosis. World J Gastroenterol 2008; 14(21): 3313-3327 [PMID: 18528929 DOI: 10.3748/wjg.14.3313] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]